AbbVie (ABBV) Upgraded at ValuEngine

ValuEngine upgraded shares of AbbVie (NYSE:ABBV) from a hold rating to a buy rating in a research note issued to investors on Friday.

A number of other equities research analysts have also commented on the company. Jefferies Group upped their target price on AbbVie from $107.00 to $115.00 and gave the company a buy rating in a research report on Monday, October 16th. BMO Capital Markets set a $66.00 price objective on AbbVie and gave the stock a hold rating in a research report on Friday, October 27th. BidaskClub upgraded AbbVie from a buy rating to a strong-buy rating in a research report on Saturday, November 11th. Piper Jaffray Companies upped their price objective on AbbVie to $115.00 and gave the stock an overweight rating in a research report on Friday, October 27th. Finally, SunTrust Banks restated a buy rating on shares of AbbVie in a research report on Monday, October 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. AbbVie presently has an average rating of Buy and an average target price of $117.26.

Shares of AbbVie (NYSE:ABBV) opened at $109.51 on Friday. The company has a market capitalization of $174,570.00, a P/E ratio of 26.58, a P/E/G ratio of 1.09 and a beta of 1.61. AbbVie has a 52-week low of $60.05 and a 52-week high of $125.86. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, January 26th. The company reported $1.48 EPS for the quarter, beating the Zacks’ consensus estimate of $1.44 by $0.04. The firm had revenue of $7.74 billion for the quarter, compared to analyst estimates of $7.53 billion. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. AbbVie’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.20 earnings per share. equities analysts expect that AbbVie will post 7.46 EPS for the current year.

In other news, EVP Michael Severino sold 25,633 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the completion of the transaction, the executive vice president now directly owns 114,922 shares of the company’s stock, valued at approximately $10,881,964.18. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total value of $20,512,323.93. Following the transaction, the chairman now directly owns 492,030 shares of the company’s stock, valued at $46,255,740.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 476,376 shares of company stock worth $45,580,873. Insiders own 0.23% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Capital Research Global Investors raised its stake in AbbVie by 1.2% in the 2nd quarter. Capital Research Global Investors now owns 178,274,835 shares of the company’s stock valued at $12,926,708,000 after purchasing an additional 2,130,919 shares during the last quarter. Vanguard Group Inc. raised its stake in AbbVie by 3.3% in the 2nd quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock valued at $8,405,409,000 after purchasing an additional 3,706,941 shares during the last quarter. BlackRock Inc. raised its stake in AbbVie by 2.0% in the 2nd quarter. BlackRock Inc. now owns 94,074,962 shares of the company’s stock valued at $6,821,375,000 after purchasing an additional 1,864,418 shares during the last quarter. Orbis Allan Gray Ltd raised its stake in AbbVie by 35.7% in the 2nd quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock valued at $921,233,000 after purchasing an additional 3,340,038 shares during the last quarter. Finally, Woodford Investment Management Ltd raised its stake in AbbVie by 8.6% in the 2nd quarter. Woodford Investment Management Ltd now owns 11,854,758 shares of the company’s stock valued at $859,589,000 after purchasing an additional 937,500 shares during the last quarter. 69.54% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “AbbVie (ABBV) Upgraded at ValuEngine” was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.thestockobserver.com/2018/02/06/abbvie-abbv-upgraded-at-valuengine.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply